Boosters and test demand — coupled with lower COVID-19 treatment costs — drove CVS profit up 33% in Q4

Boosters and test demand — coupled with lower COVID-19 treatment costs — drove CVS profit up 33% in Q4

People flocked to get booster shots as the omicron variant drove a sharp increase in testing, boosting revenue for CVS' drugstore segment. Meanwhile, its payer arm reported lower-than-expected COVID-19 treatment costs.